Stockscreener 앱 받기
9.85
2.67%
-0.27
시간 외 거래:
9.85
Lyell Immunopharma Inc 주식(LYEL)의 최신 뉴스
Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet - Eastern Progress
A cancer-therapy talk will stream live Sept. 15 from Lyell Immunopharma. - Stock Titan
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference - Yahoo Finance
H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy - Investing.com
Lyell completes LYL273 manufacturing transfer, eyes 2027 FDA meeting By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Lyell Immunopharma CMO David Shook sells $6,350 in shares By Investing.com - Investing.com South Africa
Lyell Immunopharma CMO David Shook sells $6,350 in shares - Investing.com
Lyell Immunopharma (LYEL) CMO sells shares to cover taxes - Stock Titan
Lyell Immunopharma (LYEL) awards CMO new 47,500-share option - Stock Titan
Lyell Immunopharma (LYEL) CMO discloses stock, RSUs and option awards - Stock Titan
Lyell completes LYL273 manufacturing transfer, eyes 2027 FDA meeting - investing.com
Lyell Immunopharma advances LYL273 CAR T program - TipRanks
Lyell Immunopharma Completes Manufacturing Transfer for - GlobeNewswire
Lyell Immunopharma, Inc. (LYEL) Stock Price & News - Syfe
Lyell Immunopharma stock holds steady as investors await fresh clinical and cash-flow signals - AD HOC NEWS
This Insider Has Just Sold Shares In Lyell Immunopharma - simplywall.st
Lyell Immunopharma (LYEL) CEO sells shares for taxes, keeps 63,899 - Stock Titan
Lyell (LYEL) Outlook: Closes 4.57% Lower at $14.82 in the Latest Session; Next Session: the $14.08 to $15.56 Range Remains in Focus at the ClosePassive Flow - vinanet.vn
Lyell (LYEL) Technicals: Ends Up by 1.17% at $15.53 on the Day; Boundary Watch: the Price Remains Bounded by the Supplied Support and Resistance in the Current UpdateVol Target Rebalance - siam.in
Lyell Immunopharma (LYEL): Foresite funds and Tananbaum report 2.7% ownership - Stock Titan
Citizens reiterates Lyell Immunopharma stock rating on pipeline progress By Investing.com - Investing.com Canada
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Lyell Immunopharma (LYEL) Slides 4.77% to $14.17 as Biotech Risk Appetite FadesTriple Top - dars.gov.et
Lyell Immunopharma VP Bulis sells $8,905 of common stock By Investing.com - Investing.com UK
Lyell Immunopharma VP Veronica Sanchez Bulis Sells 621 Shares for Tax Withholding on August 10, 2026 - Kalkine Media
Lyell Immunopharma COO Stephen J. Hill Sells Shares to Cover Tax Withholding on RSU Settlement - Kalkine Media
Lyell Immunopharma (LYEL) CSO auto-sells shares to cover RSU tax withholding - Stock Titan
Lyell Immunopharma VP Bulis sells $8,905 of common stock - Investing.com
Lyell Immunopharma CSO Executes Automatic Stock Sale to Meet Tax Withholding Requirements - Kalkine Media
Lyell Immunopharma (LYEL) VP auto-sells 621 shares to cover RSU taxes - Stock Titan
Lyell Immunopharma (LYEL) COO auto-sells 89 shares for RSU tax withholding - Stock Titan
Lyell Immunopharma (LYEL) CEO sells shares to cover RSU tax withholding - Stock Titan
Renaissance Technologies LLC Buys 76,921 Shares of Lyell Immunopharma, Inc. $LYEL - MarketBeat
LYEL Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 3.31% Share GainEarnings Quality Score - careplusvn.com
Lyell Immunopharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Lyell Immunopharma earnings beat by $0.22, revenue fell short of estimates - Investing.com Canada
Possible Signal As Lyell Immunopharma Insiders Sell US$527k In Stock - webull.com
Lyell Immunopharma (NASDAQ:LYEL) Posts Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a shareEarnings Preview - TradingView
Lyell Immunopharma: Q2 Earnings Snapshot - AOL.com
Lyell Immunopharma reports Q2 2026 net loss $44.8M, cash $228.0M; clinical milestones advance - TradingView
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 - manilatimes.net
BRIEF-Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million - TradingView
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
Lyell Immunopharma (NASDAQ:LYEL) Earns Buy Rating from Analysts at Stifel Nicolaus - MarketBeat
Stifel Initiates Lyell Immunopharma(LYEL.US) With Buy Rating, Announces Target Price $36 - Moomoo
Stifel Initiates Lyell Immunopharma at Buy With $36 Price Target - Yahoo Finance
LYELL IMMUNOPHARMA, INC. : STIFEL INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $36 - Bitget
Stifel initiates Lyell Immunopharma stock with buy rating on CAR T therapy - Investing.com South Africa
LYEL Q2'26 Earnings: revenue estimate is 4.60K USD - TradingView
Lyell Immunopharma (LYEL) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Price to book forward of Lyell Immunopharma, Inc. – NASDAQ:LYEL - TradingView
Form 4 Lyell Immunopharma Inc For: 27 July By Investing.com - Investing.com Nigeria
Lyell Immunopharma, Inc. (LYEL) holder pays broker with 44,000 shares - Stock Titan
3.06%
2.55%
자본화:
|
볼륨(24시간):